In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

William Masters

Graduate Fellow

London, UK

Latest From William Masters

Elicera To Advance Next-Gen Cell Therapies Following IPO

Sweden-based Elicera Therapeutics is developing next-generation oncolytic viruses and “fourth-generation” CAR-T cells. CEO Jamal El-Mosleh sat down with In Vivo ahead of the company’s IPO.

Gene Therapy ImmunoOncology

Snapshot: May Highlights

A selection of articles you might have missed from May 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.

Business Strategies Companies

Execs On The Move, May 2021

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

UC Market Gets Increasingly Crowded – But High Unmet Need Remains

Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.

Launches Approvals

Alembic Reveals Pricing Challenges For US Sartans Amid Competition

Indian firm Alembic Pharmaceuticals discussed the challenges ahead for its US generics business while revealing a dramatic uptick in non-US overseas markets during its FY2021 financial earnings call.

Generic Drugs Pricing Strategies

Laevoroc Oncology Launches With Three-Pronged Strategy

Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”

Business Strategies C-Suite Speaks
See All
UsernamePublicRestriction

Register